Purpose: Mutated p53 is a tumor suppressor gene, hMLH1 is a mismatch repair gene, and hypermethylation of hMLH1 follows microsatellite instability (MSI). This research's aim is to investigate mutated p53, inactivated hMLH1 and MSI in gastric cancer and their clinicopathologic implications. Methods: Between 2003 and 2007, 618 patients underwent curative radical gastrectomy for gastric cancer at Seoul National University Bundang Hospital in Korea. We reviewed their medical charts and the pathologic reports with immunohistochemistry for p53, hMLH1 and polymerase chain reaction for MSI in 509, 499, and 561 cases, respectively. These genetic markers were statistically compared with clinicopathologic features and postoperative survival. Results: The expression ratios of mutated p53, inactivated hMLH1, and MSI were 32.8%, 8.4%, and 8.7%, respectively. Mutation of p53 occurred more frequently in aged group (over 40), differentiated group (against the non-differentiated group), intestinal type, infiltrative type and positive lymph node metastasis group. Inactivated hMLH1 occurred more frequently in aged group, differentiated group, intestinal type and expanding growth type group. MSI was found more frequently in aged group, intestinal type and expanding growth type group. All three genetic markers had no significant associations with the 5-year survival. Conclusion: We identified significant relationships between mutated p53, inactivated hMLH1, and MSI with some clinicopathologic features of gastric cancer. However, there were no apparent relationships between p53, hMLH1, and MSI and prognosis. (J Korean Surg Soc 2010;79:94-102)
INTRODUCTION
Based on remarkable advances in recent molecular biologic analysis, it is known that gastric cancer is caused where mismatch of bases occur during DNA replication.
If there are abnormal mismatch repair genes, the length of the microsatellite will be lengthened or shortened. This phenomenon is referred to as microsatellite instability (MSI), and is also referred to as the mutator phenotype of an abnormal mismatch repair gene.(6) Mismatch repair genes are associated with hMSH2, hMSH3, and hMLH1. (7) Indeed, there is research that MSI is caused by inactivation of the hMLH1 gene induced by hypermethylation. (8, 9) In the current study, we investigated the mutated p53, 
3) Immunohistochemistry
Immunohistochemical staining against mutated p53 protein (1：100, mouse monoclonal antibody DO7; DAKO, Carpinteria, CA, USA) and hMLH1 (dilution 1： 50, Clone G168-728, 1μg/ml; Pharmingen, San Diego, CA, USA) was performed using a streptavidin-biotinperoxidase complex method after an antigen retrieval process using microwaves (3 times for 5 min each) for mutated p53 protein, and using an autoclave for hMLH1.
When ＞10% of cancer cells showed nuclear staining, we considered the case to be over-expression of the p53 gene product or loss of hMLH1 expression.
4) Microsatellite analysis
The DNA of cancerous tissue from 560 of 618 patients with consecutive gastric cancers was obtained from formalin-fixed, paraffin-embedded surgical blocks. The ex- 
5) Statistical analysis
The χ
2
-test was used to determine the statistical relationship between mutated p53, inactivation of hMLH1, MSI expression, and clinicopathologic characteristics.
Survival curves were estimated using the Kaplan-Meier method, and the significance of differences between the survival curves was determined using the log-rank test.
Multivariate survival analysis was performed using the Cox proportional hazards model. Statistical significance was defined as P＜0.05. All statistical analyses were conducted using SPSS, version 15.0 (SPSS Inc., Chicago, IL, USA).
RESULTS

1) Clinicopathologic features
The clinicopathologic features are summarized in Table   1 
2) Correlation between mutated p53, inactivated hMLH1 and MSI
The association between the expression of mutated p53
protein, inactivated hMLH1, and MSI is shown in Table   2 . As mutated p53 is more highly expressed, the probability of inactivation of hMLH1 was decreased significantly (P=0.002), and the probability of detecting MSI was very small. When hMLH1 gene is inactivated, there is a significant high probability (P=0.011) that MSI (instable) is found.
3) Clinicopathologic correlations with mutated p53, inactivated hMLH1, and MSI
The correlation between the expression of mutated p53, inactivated hMLH1, and MSI, and gender and age is shown in Regarding the relationship of each genetic marker with stage, lymph node (LN) metastasis, vascular invasion, neural invasion, lymphatic invasion, and overall stage is also described in Table 3 . In the case of mutated p53 over-expression, the probability of LN metastasis was significantly higher than that of wild type p53 (P=0.025).
However, no significant relationship was found between the other genetic markers and LN metastasis.
There were some clinical differences according to each genetic marker with respect to the WHO classification, Lauren's classification, and Ming' s criteria, as shown in Table 3 . In the case of the WHO classification, for *The chi-square test was used to compare all variables except mean age, which were compared using the unpaired t test; † MSI = microsatellite instability; ‡ 'Entire' was excluded in order to compare the tendency of location effectively. Bold = statistically significant P-values are indicated. convenient comparison, well differentiation and moderate differentiation were combined in the differentiated group, and signet ring cell and poorly differentiated type were combined in the undifferentiated group. We then examined whether there was a difference in the extent of differentiation according to each genetic marker. In the case of mutated p53, it was more significantly expressed in the group in which differentiation was better (P＜0.001).
The mutated p53 was more expressed in the group of 
4) Survival analysis
Statistically significant variables were depth of tumor, LN metastasis, TNM stage, lymphatic invasion, and perineural invasion variables examined by univariate survival analysis.
The over-expressed mutated p53, inactivation of hMLH1, and MSI was not related with survival significantly (Fig. 2∼   4) . On multivariate analysis, TNM stage, lymphatic invasion and perineural invasion were remained significantly associated with survival (Table 4) . In conclusion, in this research, we couldn't find any possibility for the independent prognostic factors about p53, hMLH1 and MSI. But three genetic markers are correlated significantly with some clinicopathologic factors that can affect prognosis, like tumor differentiation, type and especially LN metastasis. This means that these genetic markers can affect the tumor aggressiveness. So if further studies are followed, detection of these genetic markers can be helpful for tailored treatment plan for each patient.
DISCUSSION
